---
title: "Feilu announced a pre-loss, expecting an annual net loss of 82 million to 122 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225559411.md"
description: "According to the Zhitong Finance APP, Feilu disclosed its performance forecast for 2024, expecting a net loss attributable to shareholders of the listed company of between 82 million yuan and 122 million yuan; the net loss after deducting non-recurring gains and losses is expected to be between 82.8 million yuan and 123 million yuan"
datetime: "2025-01-20T13:11:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225559411.md)
  - [en](https://longbridge.com/en/news/225559411.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225559411.md)
generator: "portal-rs"
---

# Feilu announced a pre-loss, expecting an annual net loss of 82 million to 122 million yuan

According to the Zhitong Finance APP, Feilu (300665.SZ) disclosed its performance forecast for 2024, expecting a net loss attributable to shareholders of the listed company of between 82 million yuan and 122 million yuan; the net loss after deducting non-recurring gains and losses is expected to be between 82.8 million yuan and 123 million yuan

### Related Stocks

- [300665.CN](https://longbridge.com/en/quote/300665.CN.md)

## Related News & Research

- [METALS-Aluminium climbs to three-week high as tightness back in focus](https://longbridge.com/en/news/297896177.md)
- [08:43 ETSCANOLOGY Sets New Benchmarks in Large-Scale and Portable 3D Measurement with TrackScan Sharp-Z and TrackScan GO](https://longbridge.com/en/news/298040497.md)
- [US Cocoa Futures (COCOA-F) Volatility Intensified on Sep 2: What to Watch](https://longbridge.com/en/news/297778138.md)
- [Egetis says new Emcitate clinical data from Triac Trial II, ReTRIACt to be presented at September congresses](https://longbridge.com/en/news/297996002.md)
- [Tezos to Launch Post-Quantum Testnet in September](https://longbridge.com/en/news/297946567.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**